查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
Molnupiravir市场-行业规模,份额,趋势,机会,预测,2017-2027,按应用,分销渠道(医院药房,零售,线上药房),地区
市场调查报告书
商品编码
1228260

Molnupiravir市场-行业规模,份额,趋势,机会,预测,2017-2027,按应用,分销渠道(医院药房,零售,线上药房),地区

Molnupiravir Market-Global Industry Size, Share, Trends, Opportunity, & Forecast, 2017-2027 Segmented By Application (Influenza, Ebola, COVID-19, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region
出版日期: | 出版商: TechSci Research | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

在 2023 年至 2027 年的预测期内，由于 COVID-19 病例数量不断增加，对有效药物的需求不断增长，因此 molnupiravir 的全球市场可能会出现令人瞩目的增长。

全球 molnupiravir 市场在未来 5 年内增长，原因是该疾病的高流行率和病毒变异使患者的病情复杂化，导致严重的感染状况并导致人们死亡。促进它。 此外，各种製药和生物技术公司为开发潜在的抗病毒药物而增加的研发活动预计将推动市场增长。

越来越多的 COVID-19 病例推动了市场增长

COVID-19 阳性病例数量的增加将是未来五年推动全球 molnupiravir 市场增长的关键因素。 有效的免疫接种和预防措施减缓了病例激增的速度。 然而，越来越多的病毒亚种和对人体的影响越来越大，增加了对 molnupiravir 等高效药物的需求，推动了未来五年全球 molnupiravir 市场的增长。

截至 2022 年 5 月 24 日，全球有 5.2837 亿 CVID-19 患者，其中 8511 万在美国。 由于在美国有如此多的人被感染，美国政府急于允许将 mornupiravir 用于患有轻度 COVID-19 症状的患者。 当这种口服胶囊首次上市时，人们担心会出现副作用。 从那时起，该药物的行业因其相对于其他疗法的可承受性而不断扩大，并且已经批准的 III 期人体试验导致该药物在预测期内显着增长。

市场进一步增长的投资和进展

製药行业不断增加的投资以及消费者在有效药物开发和抗病方面的支出不断增加，将在未来五年内推动全球 molnupiravir 市场的增长。 消费者渴望适应更先进、高效的药物。 如果这些药物在当地医药市场上价格合理且可用，更高效的分销渠道将在未来五年内进一步加速全球 molnupiravir 市场的增长。

2021 年，在获得美国食品和药物管理局的紧急使用授权后，大约七週内向美国政府提供了超过 300 万疗程的 molnupiravir。 由于北美地区传染病爆发的次数不断增加，对药品的需求很高。 其他药物的进一步发展和创新 COVID-19 限制性药物的进步可能是抑制市场增长的因素。

可自定义

TechSci Research 根据市场数据为公司的特定需求提供定制服务。 该报告可以定制为：

公司资讯

  • 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析。

内容

第 1 章概述

第 2 章研究方法论

第 3 章 COVID-19 对全球 Mornupiravir 市场的影响

第 4 章执行摘要

第 5 章客户反馈

  • 影响 molnupiravir 需求的因素
  • molnupiravir 来源的选择
  • 从哪里获取资讯
  • 阻碍 molnupiravir 传播的因素
  • 品牌知名度

第 6 章 Mornupiravir 药理学概述

  • 作用机制
  • 吸收
  • 分布量
  • 蛋白质结合
  • 新陈代谢
  • 排泄途径
  • 半衰期
  • 清关

第 7 章临床试验

  • 正在进行的临床试验
  • 完成临床试验
  • 完成临床试验
  • 临床试验分析

第 8 章专利分析

  • 专利状态（2017-2021 年）
  • 已申请专利

第 9 章 Mornupiravir 的全球市场展望

  • 市场规模和预测
    • 按金额/数量
  • 市场份额和预测
    • 按应用（流感、埃博拉、COVID-19 等）
    • 按分销渠道（住院药房、零售药房、在线药房）
    • 按公司分类（2021 年）
    • 按地区
  • 价格分析
  • 产品市场地图

第 10 章 Mornupiravir 在北美的市场展望

  • 市场规模和预测
    • 按金额/数量
  • 市场份额/预测
    • 通过申请
    • 按分销渠道
    • 按国家
  • 价格分析
  • 北美分析
    • 美国
    • 墨西哥
    • 加拿大

第 11 章欧洲 Mornupiravir 的市场展望

  • 市场规模和预测
    • 按金额/数量
  • 市场份额/预测
    • 通过申请
    • 按分销渠道
    • 按国家
  • 价格分析
  • 欧洲国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙
    • 丹麦

第 12 章亚太地区 Mornupiravir 市场展望

  • 市场规模和预测
    • 按金额/数量
  • 市场份额和预测
    • 通过申请
    • 按分销渠道
    • 按国家
  • 价格分析
  • 亚太国家/地区分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳大利亚
    • 越南
    • 菲律宾
    • 印度尼西亚
    • 马来西亚

第 13 章：南美洲 Mornupiravir 市场展望

  • 市场规模和预测
    • 按金额/数量
  • 市场份额/预测
    • 通过申请
    • 按分销渠道
    • 按国家
  • 价格分析
  • 南美洲国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 14 章中东和非洲的 Mornupiravir 市场展望

  • 市场规模和预测
    • 按金额/数量
  • 市场份额/预测
    • 通过申请
    • 按分销渠道
    • 按国家
  • 价格分析
  • MEA：国家分析
    • 南非的 Molnupiravir
    • 沙特阿拉伯的 Molnupiravir
    • 阿联酋的 Molnupiravir
    • 肯尼亚的 Molnupiravir

第 15 章市场动态

  • 促进因素
  • 任务

第 16 章新兴市场的市场趋势与发展

第 17 章市场趋势竞争态势

  • 公司概况
    • 公司详情
    • 财务资讯（合併基础）
    • 主要市场焦点和地域分布
    • 符合条件的产品定价
    • 市场定位
  • Merck Sharp & Dohme Corp.
  • Everest Organics Limited
  • Optimus Drugs Pvt Ltd.
  • Dr. Reddy's Laboratories Ltd
  • Cipla Limited
  • Mylan N.V.
  • Emcure Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Limited
  • Hetero Drugs Ltd.
  • Torrent Pharmaceuticals Ltd.

第 18 章战略建议

简介目录
Product Code: 10604

Global Molnupiravir market may register impressive growth in the forecast period, 2023-2027, due to rising demands for effective pharmaceuticals for the rising cases of COVID-19. The high prevalence of the disease coupled with the viral variant complicates the conditions of the patients and thus leading to severe conditions of the infection and causing death for the population, driving the growth of the global Molnupiravir market in the upcoming five years. Furthermore, increasing research and development activities by various pharmaceutical & biotechnology players for the development of potential antiviral drugs is anticipated to foster market growth.

Molnupiravir is an orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV2, the causative agent of COVID-19. In simpler terms, the pharmaceutical product Molnupiravir is an orally administered drug that has higher potency as compared to other antiviral drugs against COVID-19. The drug has the chemical composition of mRNA that can act against the viral, and COVID infection-causing virus' RNA. This RNA sequence has an effect against the new SARS-CoV2 too is thus used for controlling the effects of COVID-19.

Rising Instances of COVID-19 Drives Market Growth

Growing instances of COVID-19-positive cases are a major factor driving the growth of the global Molnupiravir market in the upcoming five years. Although through effective vaccinations and the use of precautionary steps, the rapid growth in the cases has been controlled. Although, growing variants of the virus and its evolving effect on the human body affect lives, and thus the demand for efficient pharmaceuticals such as Molnupiravir increases thereby supporting the growth of the global Molnupiravir market in the next five years.

As of 24th May 2022, there are already 528.37 million CVID-19 cases around the world, out of which 85.11 million cases belong to the United States itself. With the viral infection affecting such a large population in the country, the United States government had hastily authorized the administration of Molnupiravir to patients suffering from the mild symptoms of COVID-19. The orally administered capsules had certain concerns and side effects in their early phase-outs. Soon followed by the affordability of the drug as compared to other available treatment drugs, the industry for the drug expanded and with Clinical Phase III human trials already approved, the drug is expected to substantially grow in the forecast years.

Investments & Advancement Wheel In Further Market Growth

Rising investment in the pharmaceutical industry and growing expenses from the consumers toward effective drug development and overcoming the disease drives the growth of the global Molnupiravir market in the upcoming five years. Consumers are eager to adapt to more advanced, highly effective, and efficient drugs. If these drugs are affordable and are available in the local pharmaceutical markets, the distribution channel efficiency further fuels the growth of the global Molnupiravir market in the next five years.

In 2021, more than 3 million courses of Molnupiravir were supplied to the U.S. government within approximately 7 weeks of receiving emergency use authorization from the U.S. food and drug administration. The demands for drugs are high in the North American region looking at the growing instances of the cases in the country. Further evolutions in other pharmaceuticals and advancements in the innovative COVID-19 restricting drugs may create restraint on the growth of the market.

Market Segmentation

The global Molnupiravir market segmentation is based on application, distribution channel, regional distribution, and competitive landscape. Based on application, the market is fragmented into influenza, Ebola, COVID-19, and others. By distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The market analysis also studies the regional segmentation, divided among the Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

Merck Sharp & Dohme Corp., Everest Organics Limited, Optimus Drugs Pvt Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Mylan N.V., Emcure Pharmaceuticals Ltd., Sun Pharmaceutical Industries Limited, Hetero Drugs Ltd., Torrent Pharmaceuticals Ltd., are enlisted in a partial list of major market players of the global Molnupiravir market.

Report Scope

In this report, global Molnupiravir market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molnupiravir Market, By Type:

  • Influenza
  • Ebola
  • COVID-19
  • Others

Molnupiravir Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Molnupiravir Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Vietnam
    • Philippines
    • Indonesia
    • Malaysia
  • Europe
    • France
    • Germany
    • United Kingdom
    • Spain
    • Italy
    • Denmark
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kenya

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Molnupiravir market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Molnupiravir Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Factors Contributing to Demand of Molnupiravir
  • 5.2. Choice of Source for Procuring Molnupiravir
  • 5.3. Source of Information
  • 5.4. Barriers to Adoption of Molnupiravir
  • 5.5. Brand Awareness

6. Pharmacodynamic Overview of Molnupiravir

  • 6.1. Mechanism of Action
  • 6.2. Absorption
  • 6.3. Volume of Distribution
  • 6.4. Protein Binding
  • 6.5. Metabolism
  • 6.6. Route of Elimination
  • 6.7. Half Life
  • 6.8. Clearance

7. Clinical Trials

  • 7.1. Ongoing Clinical Trials
  • 7.2. Completed Clinical Trials
  • 7.3. Terminated Clinical Trials
  • 7.4. Clinical Trial Analysis

8. Patent Analysis

  • 8.1. Patent Granted (2017-2021)
  • 8.2. Patent Applications Filed

9. Global Molnupiravir Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application (Influenza, Ebola, COVID-19, Others)
    • 9.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 9.2.3. By Company (2021)
    • 9.2.4. By Region
  • 9.3. Pricing Analysis
  • 9.4. Product Market Map

10. North America Molnupiravir Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. Pricing Analysis
  • 10.4. North America: Country Analysis
    • 10.4.1. United States Molnupiravir Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value & Volume
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Application
        • 10.4.1.2.2. By Distribution Channel
    • 10.4.2. Mexico Molnupiravir Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value & Volume
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Application
        • 10.4.2.2.2. By Distribution Channel
    • 10.4.3. Canada Molnupiravir Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value & Volume
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Application
        • 10.4.3.2.2. By Distribution Channel

11. Europe Molnupiravir Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Application
    • 11.2.2. By Distribution Channel
    • 11.2.3. By Country
  • 11.3. Pricing Analysis
  • 11.4. Europe: Country Analysis
    • 11.4.1. France Molnupiravir Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value & Volume
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Application
        • 11.4.1.2.2. By Distribution Channel
    • 11.4.2. Germany Molnupiravir Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value & Volume
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Application
        • 11.4.2.2.2. By Distribution Channel
    • 11.4.3. United Kingdom Molnupiravir Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value & Volume
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Application
        • 11.4.3.2.2. By Distribution Channel
    • 11.4.4. Italy Molnupiravir Market Outlook
      • 11.4.4.1. Market Size & Forecast
        • 11.4.4.1.1. By Value & Volume
      • 11.4.4.2. Market Share & Forecast
        • 11.4.4.2.1. By Application
        • 11.4.4.2.2. By Distribution Channel
    • 11.4.5. Spain Molnupiravir Market Outlook
      • 11.4.5.1. Market Size & Forecast
        • 11.4.5.1.1. By Value & Volume
      • 11.4.5.2. Market Share & Forecast
        • 11.4.5.2.1. By Application
        • 11.4.5.2.2. By Distribution Channel
    • 11.4.6. Denmark Molnupiravir Market Outlook
      • 11.4.6.1. Market Size & Forecast
        • 11.4.6.1.1. By Value & Volume
      • 11.4.6.2. Market Share & Forecast
        • 11.4.6.2.1. By Application
        • 11.4.6.2.2. By Distribution Channel

12. Asia-Pacific Molnupiravir Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value & Volume
  • 12.2. Market Share & Forecast
    • 12.2.1. By Application
    • 12.2.2. By Distribution Channel
    • 12.2.3. By Country
  • 12.3. Pricing Analysis
  • 12.4. Asia-Pacific: Country Analysis
    • 12.4.1. China Molnupiravir Market Outlook
      • 12.4.1.1. Market Size & Forecast
        • 12.4.1.1.1. By Value & Volume
      • 12.4.1.2. Market Share & Forecast
        • 12.4.1.2.1. By Application
        • 12.4.1.2.2. By Distribution Channel
    • 12.4.2. India Molnupiravir Market Outlook
      • 12.4.2.1. Market Size & Forecast
        • 12.4.2.1.1. By Value & Volume
      • 12.4.2.2. Market Share & Forecast
        • 12.4.2.2.1. By Application
        • 12.4.2.2.2. By Distribution Channel
    • 12.4.3. South Korea Molnupiravir Market Outlook
      • 12.4.3.1. Market Size & Forecast
        • 12.4.3.1.1. By Value & Volume
      • 12.4.3.2. Market Share & Forecast
        • 12.4.3.2.1. By Application
        • 12.4.3.2.2. By Distribution Channel
    • 12.4.4. Japan Molnupiravir Market Outlook
      • 12.4.4.1. Market Size & Forecast
        • 12.4.4.1.1. By Value & Volume
      • 12.4.4.2. Market Share & Forecast
        • 12.4.4.2.1. By Application
        • 12.4.4.2.2. By Distribution Channel
    • 12.4.5. Australia Molnupiravir Market Outlook
      • 12.4.5.1. Market Size & Forecast
        • 12.4.5.1.1. By Value & Volume
      • 12.4.5.2. Market Share & Forecast
        • 12.4.5.2.1. By Application
        • 12.4.5.2.2. By Distribution Channel
    • 12.4.6. Vietnam Molnupiravir Market Outlook
      • 12.4.6.1. Market Size & Forecast
        • 12.4.6.1.1. By Value & Volume
      • 12.4.6.2. Market Share & Forecast
        • 12.4.6.2.1. By Application
        • 12.4.6.2.2. By Distribution Channel
    • 12.4.7. Philippines Molnupiravir Market Outlook
      • 12.4.7.1. Market Size & Forecast
        • 12.4.7.1.1. By Value & Volume
      • 12.4.7.2. Market Share & Forecast
        • 12.4.7.2.1. By Application
        • 12.4.7.2.2. By Distribution Channel
    • 12.4.8. Indonesia Molnupiravir Market Outlook
      • 12.4.8.1. Market Size & Forecast
        • 12.4.8.1.1. By Value & Volume
      • 12.4.8.2. Market Share & Forecast
        • 12.4.8.2.1. By Application
        • 12.4.8.2.2. By Distribution Channel
    • 12.4.9. Malaysia Molnupiravir Market Outlook
      • 12.4.9.1. Market Size & Forecast
        • 12.4.9.1.1. By Value & Volume
      • 12.4.9.2. Market Share & Forecast
        • 12.4.9.2.1. By Application
        • 12.4.9.2.2. By Distribution Channel

13. South America Molnupiravir Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value & Volume
  • 13.2. Market Share & Forecast
    • 13.2.1. By Application
    • 13.2.2. By Distribution Channel
    • 13.2.3. By Country
  • 13.3. Pricing Analysis
  • 13.4. South America: Country Analysis
    • 13.4.1. Brazil Molnupiravir Market Outlook
      • 13.4.1.1. Market Size & Forecast
        • 13.4.1.1.1. By Value & Volume
      • 13.4.1.2. Market Share & Forecast
        • 13.4.1.2.1. By Application
        • 13.4.1.2.2. By Distribution Channel
    • 13.4.2. Argentina Molnupiravir Market Outlook
      • 13.4.2.1. Market Size & Forecast
        • 13.4.2.1.1. By Value & Volume
      • 13.4.2.2. Market Share & Forecast
        • 13.4.2.2.1. By Application
        • 13.4.2.2.2. By Distribution Channel
    • 13.4.3. Colombia Molnupiravir Market Outlook
      • 13.4.3.1. Market Size & Forecast
        • 13.4.3.1.1. By Value & Volume
      • 13.4.3.2. Market Share & Forecast
        • 13.4.3.2.1. By Application
        • 13.4.3.2.2. By Distribution Channel

14. Middle East and Africa Molnupiravir Market Outlook

  • 14.1. Market Size & Forecast
    • 14.1.1. By Value & Volume
  • 14.2. Market Share & Forecast
    • 14.2.1. By Application
    • 14.2.2. By Distribution Channel
    • 14.2.3. By Country
  • 14.3. Pricing Analysis
  • 14.4. MEA: Country Analysis
    • 14.4.1. South Africa Molnupiravir Market Outlook
      • 14.4.1.1. Market Size & Forecast
        • 14.4.1.1.1. By Value & Volume
      • 14.4.1.2. Market Share & Forecast
        • 14.4.1.2.1. By Application
        • 14.4.1.2.2. By Distribution Channel
    • 14.4.2. Saudi Arabia Molnupiravir Market Outlook
      • 14.4.2.1. Market Size & Forecast
        • 14.4.2.1.1. By Value & Volume
      • 14.4.2.2. Market Share & Forecast
        • 14.4.2.2.1. By Application
        • 14.4.2.2.2. By Distribution Channel
    • 14.4.3. UAE Molnupiravir Market Outlook
      • 14.4.3.1. Market Size & Forecast
        • 14.4.3.1.1. By Value & Volume
      • 14.4.3.2. Market Share & Forecast
        • 14.4.3.2.1. By Application
        • 14.4.3.2.2. By Distribution Channel
    • 14.4.4. Kenya Molnupiravir Market Outlook
      • 14.4.4.1. Market Size & Forecast
        • 14.4.4.1.1. By Value & Volume
      • 14.4.4.2. Market Share & Forecast
        • 14.4.4.2.1. By Application
        • 14.4.4.2.2. By Distribution Channel

15. Market Dynamics

  • 15.1. Drivers
  • 15.2. Challenges

16. Market Trends & Developments

17. Competitive Landscape

  • 17.1. Company Profiles
    • 17.1.1. Company Details
    • 17.1.2. Financials (As reported)
    • 17.1.3. Key Market Focus and Geographical Presence
    • 17.1.4. Pricing of Target Products
    • 17.1.5. Market positioning
  • 17.2. Merck Sharp & Dohme Corp.
  • 17.3. Everest Organics Limited
  • 17.4. Optimus Drugs Pvt Ltd.
  • 17.5. Dr. Reddy's Laboratories Ltd
  • 17.6. Cipla Limited
  • 17.7. Mylan N.V.
  • 17.8. Emcure Pharmaceuticals Ltd.
  • 17.9. Sun Pharmaceutical Industries Limited
  • 17.10. Hetero Drugs Ltd.
  • 17.11. Torrent Pharmaceuticals Ltd.

18. Strategic Recommendations